Why Alere's Shares Fell

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of Alere (NYSE: ALR  )  lost 10% of their value today after pairing a disappointing quarterly report with lowered forward guidance.

So what: Alere's revenue came in at $691.4 million, a hair over the $690.3 million analysts were looking for. However, adjusted EPS, at $0.43, was well under the $0.53 that Wall Street expected. The company said that sales of its flu products dropped, and it was also hurt by a recall of some heart attack and heart failure tests, which are really not the sort of products you would ever want to fail when you need them.

Alere also lowered its guidance for the 2012 fiscal year to a range of $2.30 to $2.45 in EPS, which is well below the analyst consensus of $2.54.

Now what: Not only did Alere miss EPS estimates, it's also come under some scrutiny from the Food and Drug Administration, and has received a subpoena regarding its quality control methods for manufacturing the recalled products. With this sort of legal mess hanging over a weakened company, there seems little reason to buy. FDA concerns and recalls aren't a buying opportunity -- they're a warning.

Want more news and updates? Add Alere to your watchlist now.


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

DocumentId: 2103043, ~/Articles/ArticleHandler.aspx, 8/1/2014 5:12:43 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement